I

ITF Therapeutics

Develops and commercializes rare-disease therapies

Vice President - US Regulatory Affairs

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeConcord, MA, USA$330k - $370kIn-person

About the Job

Requirements

  • 15+ years of demonstrated growth and proven success leading regulatory strategy, preparing a high-impact submission, and negotiating winning labels.
  • Direct experience with FDA interactions and regulatory filings.
  • Familiarity with rare diseases, small and large molecules.
  • Thorough knowledge of FDA regulations for investigational products, IND/NDA/BLA submissions, and in-line product life-cycle management.
  • Awareness of major global regulatory frameworks, including EMA, ICH, and MHRA, and demonstrated contribution to worldwide regulatory strategy.
  • Experience working in global corporate environments and demonstrated ability to navigate and collaborate across matrixed international organizations.
  • Strong scientific writing and strategic thinking.
  • Deep understanding of FDA regulations and CTD/eCTD formats.
  • Ability to lead cross-functional teams and manage external partners in a matrixed organization.
  • Hands-on, proactive, and adaptable in a fast-paced growth-phase biotech environment.

Responsibilities

  • Lead development and implementation of US regulatory strategies in close alignment with Global Regulatory Affairs.
  • Contribute to Global regulatory strategy development and ensure effective regional implementation of Global strategy.
  • Provide Regulatory and Pharmacovigilance leadership across product development stages and translate regulatory context into actionable business strategies.
  • Own US Regulatory strategy and all FDA engagement, including scientific advice, label negotiations, submissions, lifecycle management, and maintenance of relevant operating licenses.
  • Nurture collaborative relationships with regulatory authorities and serve as the executive interface for the FDA for in-line and pipeline products.
  • Lead planning and execution of regulatory agency engagements, inspections, and communications.
  • Ensure ongoing compliance with FDA regulations, including advertising, promotion, post-market obligations, and pharmacovigilance requirements.
  • Oversee regulatory submissions, including INDs, NDAs, label updates, OPDP forms, and periodic reports.
  • Monitor the regulatory environment, share regulatory intelligence with US and Global leadership, and maintain internal guidelines to ensure compliance.
  • Oversee pharmacovigilance operations, including adverse event reporting, signal detection, risk management plans, and safety updates in collaboration with Global Safety counterparts.
  • Ensure alignment of local operating standards with Global GxP standards and governance frameworks.
  • Build, lead, and develop a US Regulatory team comprising Regulatory Strategy, Regulatory CMC, Regulatory publishing, and AdProm capabilities.
  • Serve as an organization leader and steward of corporate values and culture.
  • Build strategic collaboration with Global Regulatory Affairs and Development functions.
  • Work closely with Medical Affairs, Marketing, Legal, Clinical Operations, and other cross-functional partners to optimize product impact for patient communities.
  • Partner with the VP of Global Regulatory Affairs to align regional and global priorities.
  • Contribute to business development and due diligence by assessing regulatory options, risks, and opportunities for candidate products.

Desired Qualifications

  • An advanced scientific degree, such as a PhD, PharmD, MS, or MSN.

About the Company

ITF Therapeutics

Develops and commercializes rare-disease therapies

ITF Therapeutics is a division of Italfarmaco S.p.A. focused on developing and commercializing treatments for rare diseases in the U.S., especially Duchenne Muscular Dystrophy (DMD). The company works on early-stage research and clinical development, partnering with patient advocacy groups and clinical leaders to align programs with patient needs. Its lead program is DUVYZAT (givinostat), a histone deacetylase (HDAC) inhibitor aimed at DMD. Revenue comes from bringing these specialized therapies to market. Compared with competitors, ITF Therapeutics emphasizes collaboration with patient groups and clinicians, a pipeline-focused early-development approach, and a specialty in HDAC inhibitors for rare diseases. The company’s goal is to deliver effective treatments for rare-disease patients by advancing promising therapies through development and into commercialization.

Company size
1-10
Company stage
Not listed
Total funding
Not listed
Headquarters
Concord, NH
Founded
2024

Recently Posted Jobs

Explore more opportunities at ITF Therapeutics

See more jobs